Radiotherapy causes dose-limiting toxicity and long-term complications in rapidly renewing tissues, including the gastrointestinal tract. Currently, there is no FDA-approved agent for the prevention or treatment of radiation-induced intestinal injury. In this study, we have shown that PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration. PD treatment also enhanced LGR5 + stem cell survival and regeneration after radiation. PD was an on-target inhibitor of RB phosphorylation and blocked G 1 /S transition in the intestinal crypts. PD treatment strongly but reversibly inhibited radiation-induced p53 activation, which blocked p53-upregulated modulator of apoptosis-dependent (PUMA-dependent) apoptosis without affecting p21-dependent suppression of DNA damage accumulation, with a repair bias toward nonhomologous end joining. Further, deletion of PUMA synergized with PD treatment for even greater intestinal radioprotection. Our results demonstrate that the cell cycle critically regulates the DNA damage response and survival of intestinal stem cells and support the concept that pharmacological quiescence is a potentially highly effective and selective strategy for intestinal radioprotection.
Introduction
Small intestinal epithelium is the fastest-renewing adult tissue, with a turnover rate of 3 to 5 days in mice that is fueled by intestinal stem cells (ISCs) (1, 2) . ISCs include actively cycling crypt base columnar cells (CBCs) intermingled with Paneth cells as well as more quiescent cells located slightly above, termed +4 cells. Several genes including the Wnt targets leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) and olfactomedin 4 (Olfm4) can mark ISCs in mice (3) . Increasing evidence suggests that ISC subpopulations overlap in gene expression profiles and can interconvert upon injury or genetic ablation (3) . Genetic ablation of LGR5 cells is well tolerated during hemostasis but profoundly impairs intestinal generation after high-dose radiation (4) (5) (6) . However, the nature of radioresistant LGR5 cells and their relative contribution to intestinal regeneration remain to be elucidated (7) .
Ionizing radiation-induced (IR-induced) gastrointestinal (GI) toxicity is the primary dose-limiting factor in abdominal and pelvic radiotherapy and currently cannot be prevented or treated by any FDA-approved agent (8, 9) . The single, high-dose total-body irradiation (TBI) model has been used extensively to study IRinduced intestinal injury and regeneration in mice and revealed a key role of the ataxia telangiectasia mutated/p53 (ATM/p53) pathway in regulating intestinal radiosensitivity largely independently of bone marrow injury (1, 7) . High-dose radiation induces rapid p53/p53-upregulated modulator of apoptosis-dependent (p53/ PUMA-dependent) apoptosis in ISCs within minutes to hours, followed by a delayed nonapoptotic cell death within days during crypt generation (10, 11) . Loss of p53 or p21 exacerbates the nonapoptotic response, with elevated DNA damage when the early apoptotic response is either blocked or unaffected (12) (13) (14) .
Cell-cycle progression is driven by the combination of cyclin-dependent kinases (CDKs) and their cyclin partners. The CDK4/6/cyclin D complex is critical to the G 1 /S phase transition and is responsible for phosphorylation of the retinoblastoma (RB) protein, the activation of the E2F family of transcription factors, and the subsequent synthesis of factors necessary for DNA replication (15) . Therefore, the catalytic activity of CDK4/6 regulates the commitment to cell division, which is hyperactivated in many human cancers as a result of alternations in cyclins, CDKs, or upand downstream regulators such as p53 and RB (16) . As a result, small-molecule, selective CDK4/6 inhibitors (CDKi) have been developed in recent years as potential anticancer drugs, including orally bioavailable PD 0332991 (palbociclib, referred to hereafter as PD) and LEE011 (LEE). PD suppresses the growth of xenografts via an RB-dependent mechanism (17) and received accelerated FDA approval in 2015 for the treatment of estrogen receptor-positive (ER-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer. However, the effects of CDKi on normal tissues are not well studied.
Radiation induces DNA double-strand breaks (DSBs) and rapidly activates the G 1 /S checkpoint via ATM-and p53-dependent mechanisms in normal cells (18, 19) . Conversely, elegant studies in yeast and mammalian cells demonstrate that the induction of G 1 arrest or genetic ablation of CDKs suppresses radiosensitivity and influences the DNA damage response (DDR) and the choice of DNA repair pathways, while the in vivo significance and underlying mechanisms remain unclear (reviewed in ref. 20) . We hypothesize that pharmacologic inhibition of the G 1 /S transition Radiotherapy causes dose-limiting toxicity and long-term complications in rapidly renewing tissues, including the gastrointestinal tract. Currently, there is no FDA-approved agent for the prevention or treatment of radiation-induced intestinal injury. In this study, we have shown that PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration. PD treatment also enhanced LGR5 + stem cell survival and regeneration after radiation. PD was an on-target inhibitor of RB phosphorylation and blocked G 1 /S transition in the intestinal crypts. PD treatment strongly but reversibly inhibited radiation-induced p53 activation, which blocked p53-upregulated modulator of apoptosis-dependent (PUMA-dependent) apoptosis without affecting p21-dependent suppression of DNA damage accumulation, with a repair bias toward nonhomologous end joining. Further, deletion of PUMA synergized with PD treatment for even greater intestinal radioprotection. Our results demonstrate that the cell cycle critically regulates the DNA damage response and survival of intestinal stem cells and support the concept that pharmacological quiescence is a potentially highly effective and selective strategy for intestinal radioprotection.
mental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI88410DS1), a schedule chosen empirically so that the last dose would be administered prior to resumption of crypt proliferation, around 24 hours (1, 11, 14) . All vehicle-treated mice died 5-7 days after treatment and had an average weight loss of 24% by day 5 ( Figure 1 , B and C), which is characteristic of lethal GI injury. In contrast, 60% of mice in the PD-treated group survived at least 40 days after treatment, with a significant reduction in weight by day 5 that was restored within 10 days to their pre-ABI weight (Figure 1 , B and C, and data not shown). The survival rate of mice after 15 Gy ABI or TBI is similar and independent of the BM injury observed (21, 22) . However, the ABI model results in uneven GI injury, thus precluding quantitative histological or molecular analysis. Using the well-characterized TBI model (1, prior to radiation will protect the GI epithelium by modulating the DDR. In this study, we discovered that small-molecule CDK4/6 inhibitors potently protect against radiation-induced lethal GI injury by modulating p53 and DNA repair pathways. Our data provide insights into the regulation of the DDR by the cell cycle and potential pharmacological approaches for the selective protection of normal intestinal epithelium and stem cells.
Results

PD potently protects against IR-induced lethal GI injury.
To determine the effect of PD on radiation-induced lethal GI injury, we first monitored the survival of mice after 15 Gy abdominal irradiation (ABI). The compound was given twice before (28 hours and 4 hours) and once after (20 hours) radiation ( Figure 1A and Supple- numbers in the control group ( Figure 3, A and B) . Interestingly, the few cleaved caspase-3 + crypt cells in the PD-treated mice were found mostly above the CBCs ( Figure 3C ). To rule out the possibility that these protective effects were PD specific, we used another selective CDK4/6 inhibitor, LEE, which is in the late stages of clinical development (Supplemental Figure 1A) . LEE, which was administered on the same schedule, also reduced crypt apoptosis and proliferation and increased crypt regeneration ( Figure 3D and Supplemental Figure 3 , A-C). p53/PUMA is the major mediator of IR-induced crypt apoptosis (11) . We found that PD or LEE treatment strongly inhibited the accumulation of p53 and its targets such as p21, PUMA, Bax, and Bak within 4 hours ( Figure 3E ). Realtime RT-PCR confirmed reduced mRNA expression of p53 targets ( Figure 3F ), but not p53 (Supplemental Figure 3D ). The levels of antiapoptotic BCL-2 members were not consistently affected by IR or PD (data not shown). PD treatment also suppressed IRinduced phosphorylation of JNK, ERK, and GSK3 and increased the phosphorylation of NF-κB and p38 at 4 hours (Supplemental Figure 3E ). These data demonstrate that CDKs profoundly suppress IR-induced p53 activation and apoptosis and influence the stress responses in intestinal crypts.
PD protects LGR5 stem cells. We then used Lgr5-EGFP-IRESCreERT2 mice (25) to examine the effects of PD on ISCs. Radiation induced a greater than 85% loss of LGR5 cells by 48 hours, which was significantly suppressed in the PD group ( Figure 4 , A and B, and Supplemental Figure 4A ). TUNEL and GFP (LGR5) double staining indicated extensive apoptosis of LGR5 cells 4 and 24 hours after radiation, which was suppressed in the PD-treated group (Figure 4, C and D) . Therefore, LGR5+ CBCs were radiosensitive, not resistant (26) , while some LGR5 +4 cells were resistant ( Figure 4A ). The increased cell death we observed in the PD-treated group at 24 hours was likely caused by mitotic cell death as a result of rapid recovery of intestinal proliferation ( Figure 2 , B and C) with unrepaired DNA or DNA damage accumulation. We then analyzed the contribution of LGR5 cells to crypt regeneration after IR by lineage tracing in Lgr5-EGFP-ERT2 Rosa-LacZ reporter mice with a single injection of tamoxifen 18 hours before radiation. The fraction of LacZ + crypts increased by over 2-fold in the PD-treated group (from 16% to 33%) ( Figure 4 , E and F). The reporter (LGR5-GFP) is expressed in 30% to 35% of crypts (25) , suggesting that nearly all crypts were from LGR5 + cells in the PD-treated group. Coupled with a greater than 2-fold (from 15 to 35; Figure 1H ) increase in regenerated crypts, the LGR5-specific contribution in the PD group was calculated to be 4.8-fold higher than that seen in the control group. Using Olfm4 RNA ISH (27), we confirmed a strong protection by PD against the loss of Olfm4 + cells and crypts at 48 hours ( Figure  4 , G and H, and Supplemental Figure 4B ). The location-specific Olfm4 single-molecule signals also indicated a greater than 2-fold protection, reducing the loss from over 85% to 30% (area) (Supplemental Figure 4 , C and D). These results indicate that LGR5 stem cells are the major target of PD-mediated intestinal protection.
PD prevents DNA damage accumulation. Our previous work established that DNA damage at 24 hours strongly correlates with crypt regeneration after 15 Gy TBI (14) . To examine the potential role of DNA damage and repair in PD-enhanced crypt regeneration, we first detected DNA DSBs by γH2AX staining. The levels of γH2AX + cells were similar in the PD and control groups until the 7), we found that the PD group displayed better-preserved intestinal structure, a 2 fold-increase in surviving crypts, and taller villi ( Figure 1 , D-F). This was correlated with an approximately 2-fold increase in regenerated crypts, as measured by a microcolony assay ( Figure 1 , G and H). Nearly all crypts were regenerated de novo following the loss of existing ones at this dose in WT mice (1, 11) . PD also significantly prolonged the survival of mice after 15 Gy TBI (Supplemental Figure 1B) . Therefore, PD potently prevents radiation-induced lethal GI injury. PD treatment profoundly changes intestinal proliferation kinetics. To understand the effects of PD on crypt regeneration, we monitored proliferation kinetics using the BrdU pulse assay, which captures S-phase entry and DNA replication. In the vehicle-treated group, robust crypt proliferation decreased by nearly 90% (1,500 to 30) 72 hours after TBI, followed by the appearance of regenerated crypts by 96 hours as previously described (Figure 2A) (1, 7) . In the PD-treated group, the curve was reversed, as crypt proliferation was halted prior to radiation and gradually recovered, reaching twice that of the control group by 96 hours (Figure 2 , A and B, and Supplemental Figure 2A ). Interestingly, PD was very potent, reducing the fraction of BrdU + crypts from 100% to 23% prior to radiation (Supplemental Figure 2B and Supplemental Figure 2C ). Exposure to 15 Gy TBI causes crypt loss between 24 and 96 hours (1, 7) (Supplemental Figure 2D) , therefore, intestinal proliferation was quantified using 6-8 cross sections in each animal. Crypt proliferation in mice receiving PD but no TBI fully recovered within 48 hours ( Figure 2B and Supplemental Figure 2E ). The proliferation index of CBCs was also opposite in the control and PD groups. In the control group, the proliferation rate of CBCs started high and declined within 24 hours, while it started very low in the PD-treated group and increased to a significantly higher level than was observed in the controls (Figure 2 , C-E). BrdU labels both ISCs and transit-amplifying (TA) cells, which greatly outnumber ISCs.
β-Catenin is an important signal transducer of the Wnt pathway, and its carboxy terminal phosphorylation (Ser552) promotes its nuclear accumulation and ISC activation, but is absent in TA cells (23, 24) . In unirradiated mice, roughly 80 such cells were found in a cross section, or 1 cell in approximately 40% of crypts ( Figure 2G and Supplemental Figure 2F ) (23, 24) . We therefore examined the kinetics of phosphorylated β-catenin + (p-β-catenin + ) cells at 4, 24, and 96 hours after radiation, key time points corresponding to ISC inactivation, activation, and peak regeneration. These cells completely disappeared (from ~80 to 0) 4 hours after radiation in both the PD-treated and control groups, indicating that ISCs were fully inactivated. However, in the PD group, their number was 80% lower 24 hours and 200% higher 96 hours after radiation compared with numbers in the control (Figure 2 , F and G, and Supplemental Figure 2F ). These data demonstrate that PD profoundly alters intestinal proliferation kinetics in response to radiation, which is associated with suppressed ISC activation and improved regeneration.
PD blocks IR-induced apoptosis and p53 elevation. The increase in regenerated crypts suggests that CDKi treatment enhances stem cell survival. We therefore examined crypt apoptosis by TUNEL and cleaved caspase-3 staining 4 and 24 hours after radiation. In the PD-treated group, the number of TUNEL+ or cleaved caspase-3 + crypt cells decreased dramatically compared with the 4-hour point, but were significantly lower in the PD-treated group at 24 hours (Supplemental Figure 5A) , consistent with decreased DNA damage accumulation as indicated by γH2AX and 53BP1 foci ( Figure 5A and Supplemental Figure 5B ). Inhibition of CDKs or G 1 arrest can favor nonhomologous end joining (NHEJ) by inhibiting homologous recombination-related (HR-related) targets such as checkpoint kinase 1 (CHK1) and breast cancer 1 (BRCA1) in model organisms (20) . The formation of BRCA1 and RAD51 foci, but not DNA-dependent protein kinase catalytic subunit (DNA-PKcs) foci, in crypt cells was strongly suppressed in the PD-treated group at 4 hours, while it was similar in the CBC (+1-4) and TA zones (+5-9) (Supplemental Figure 5D) . Because of significant CBC loss The Journal of Clinical Investigation induced quiescence prior to radiation (Supplemental Figure 6D) . PD treatment corrected the radioresistant DNA synthesis observed in p53-KO and p21-KO crypts (11, 14) ( Figure 6B and Supplemental Figure 6B ). These results strongly support the idea that PD elicits a p53-and p21-dependent synergy to preserve the ISC quantity and quality necessary for intestinal recovery from radiation by suppressing PUMA-dependent apoptosis and DNA damage accumulation beyond the cell-cycle kinetics, per se.
R E S E A R C H A R T I C L E
Discussion
Radiation remains one of the most widely used cancer treatments, while normal tissue toxicities are often dose limiting and can lead to long-term complications. There is currently no FDA-approved agent that prevents or treats radiotherapy-induced GI toxicity (8, 9) . The CDKi PD has recently been approved by the FDA for cancer treatment, and more agents are in development to target the overactive G 1 /S transition, which is the commitment step to DNA replication. In this study, we demonstrate that CDKi strongly protects against IR-induced lethal intestinal injury by inducing transient stem cell quiescence and p53 shutdown to improve stem cell quantity and quality. This is consistent with the idea that blocking p53-dependent apoptosis, but not p53-dependent protective DDR, is required to maximize intestinal radioprotection (6, 11, 14) . Our findings provide in vivo evidence that CDKs play a critical role in regulating genome stability and stem cell fate in a p53-dependent manner. Induction of stem cell quiescence might therefore be a highly selective way for normal tissue protection, but not for cancer cells that have lost p53-or RB-dependent cell-cycle control. DDR is composed of elaborate signaling networks to sense different types of DNA damage and coordinate a series of responses to preserve genome stability. These responses include activation of cell-cycle checkpoints, DNA repair, senescence, and cell death (19) and critically control cell type-specific outcomes (29) . Cell quiescence has long been known to protect hematopoietic stem cells (HSCs) against cytotoxic agents (30) (31) (32) , while the underlying mechanisms remain largely unknown. Cell-cycle modulators also protected normal cells against chemotherapy (33) . More recently, 2 groups reported that selective CDK4/6 inhibitors protect and, to a lesser extent, mitigate the hematopoietic toxicity induced by radiotherapy or chemotherapy in mice (34) (35) (36) . Another group reported that fasting protects the small intestine from chemotherapy, with reduced apoptosis and faster resolution of DSBs (37) . Consistent with these findings, our work identifies 2 prosurvival DDR mechanisms for induced quiescence via transient and perhaps selective modulation of DDR in normal cells, as discussed below.
First, our study demonstrates that induced quiescence leads to transient but nearly complete loss of p53-dependent PUMA induction and ISC apoptosis, whereas p21 or timely recovery of p21 is by 24 hours (Figure 4A ), we were unable to determine whether CBCs repair DNA better than TA cells do (26) . The levels of BRCA1 and RAD51 foci were comparable at 24 hours in the PD and control groups, while the levels of DNA-PKcs foci were reduced in the PD group ( Figure 5B and Supplemental Figure 5C ). Western blotting revealed a marked inhibition of IR-induced phosphorylation of CHK1, BRCA1, and p53, with on-target inhibition of p-RB (28) in the mucosa of PD-treated mice ( Figure 5C ). Loss of p-CHK1 probably impairs the activation of p53 (S18, mouse) and retinoblastoma-binding protein 8, endonuclease (CtIP), thus inhibiting apoptosis and the HR pathway (20) , respectively. These findings provide evidence that CDK inhibition leads to DDR tolerance, at least in part, by preventing DNA damage accumulation with NHEJ repair pathway bias in vivo, in addition to enhanced cell survival.
PD-mediated intestinal protection is modulated by the p53 pathway. Suppression of p53 activation by PD was transient, and the levels of p53 and the p53 targets PUMA and p21 recovered within 4 hours of the last treatment ( Figure 5D ). The recovery of p-AKT was slightly blunted ( Figure 5D ). Our earlier work established that p53-dependent PUMA and p21 induction after TBI regulates crypt apoptosis and DNA damage accumulation independently. p21 is essential for reducing crypt proliferation at 4 hours and prevents the nonapoptotic cell death associated with massive replication stress and aberrant mitosis during crypt regeneration from 24 to 96 hours in both WT and PUMA-KO mice (14) . We further used PUMA-KO, p21-KO, and p53-KO mice to determine the role of the p53 pathway in PD-mediated intestinal radioprotection.
Compared with WT control mice, the PD and PUMA-KO combination yielded a nearly 4-fold (22.8 to 87.8) increase in crypt survival at 96 hours ( Figure 6A and Supplemental Figure 6A ), which was associated with a greater than 80% reduction of proliferation (900 to 150) and a 20-fold reduction of crypt apoptosis (4 to 0.2) at 4 hours ( Figure 6B , Supplemental Figure 6B , and Supplemental Figure 6C ). In contrast, p21 loss completely abrogated PD-mediated crypt survival at 96 hours ( Figure 6A and Supplemental Figure 6A ), despite suppression of crypt apoptosis and proliferation at 4 hours ( Figure 6B , Supplemental Figure 6B , and Supplemental Figure 6C ). PD also suppressed premature crypt regeneration at 72 hours in p21-KO mice (Supplemental Figure 7A) , however, it completely failed to suppress abnormal mitosis (γH2AX + /p-H3 + cells), replication stress (persistent 53BP1 foci) (14) , and nonapoptotic cell death (TUNEL + / cleaved caspase-3 -) ( Figure 6 , C and D, and Supplemental Figure  7B) . Further, the benefit of PD treatment for crypt survival was also completely lost in p53-KO mice, like in p21-KO mice ( Figure 6A) , despite an inhibition of proliferation that was equally as efficient as that in p21-KO and WT mice, a further decrease in apoptosis, as was observed in PUMA-KO mice 4 hours after radiation ( Figure  6B , Supplemental Figure 6B and Supplemental Figure 6C) , and an Successful cancer treatment by radiation and chemotherapy relies on the selective killing of cancer cells, with adequate preservation of the normal tissue (52) . The p53 and RB pathways are frequently deregulated in human cancer (53) , leading to deregulated CDK4/6 activity and control of the G 1 /S transition, both of which are being targeted by CDKi (15, 16) . It is important to mention that CDKi are different from other radioprotectors such as antioxidants or growth factors, which can either protect both normal and cancers cells or exacerbate tissue injury after repeated exposures due to an accelerated cell cycle (7). Our work supports the finding that reversible CDKi induce protective DDR selectively in normal tissues with WT p53, but not in cancers with deregulated p53 (35) , and clearly warrants further experimentation.
Methods
Mice and treatment. Eight-to ten-week-old PUMA -/-(PUMA-KO), Shepherd and Associates). ABI was administered in the form of x-ray with a clinical-grade linear accelerator (Varian Medical Systems) as described previously (22) . For CDKi, PD (CT-PD2991; Chemietek) (30 mg/ml in sodium lactate buffer, pH 4.0) was given by oral gavage at a dose of 150 mg/kg BW. LEE (CT-LEE011; Chemietek) was dissolved in 0.5% methylcellulose (M0512; Sigma-Aldrich) and administered by oral gavage at a dose of 150 mg/kg. Analysis of mRNA and protein expression. Intestinal mucosa scraping and isolation of total RNA and protein extracts from mouse tissues were performed as previously described (54, 55) . Real-time RT-PCR was performed on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) with SYBR Green (Invitrogen, Thermo Fisher Scientific). Primers are listed in Supplemental Table 1 . Total protein extracts were subjected to NuPAGE gel electrophoresis (Invitrogen, Thermo Fisher Scientific), followed by Western blotting. Details on the antibodies used are provided in the Supplemental Methods.
Tissue processing, histological analysis, and TUNEL and BrdU staining. BrdU (Sigma Chemical Co.) was administered by i.p. injection to all mice 2 hours prior to sacrifice at a dose of 100 mg/kg. Tissues were harvested, fixed, and embedded in paraffin as described previously (11, 22) . Sections (5-μm) were subjected to H&E staincritical for preventing DNA damage accumulation during crypt and stem cell regeneration. DDR tolerance is important for cell and organism survival and mutagenesis (38) . Interestingly, early studies have demonstrated that distinct domains of p21 bind to CDKs and proliferating cell nuclear antigen (PCNA) to regulate the cell cycle and DNA replication and repair, respectively (39, 40) . PCNA binding improves the accuracy of translesion DNA synthesis (TLS) by decreasing the interactions of PCNA and low-fidelity TLS polymerases (41, 42) . Therefore, cell-cycle-dependent and -independent mechanisms likely work together to increase survival and repair damage before or during proliferation to avoid mitotic catastrophe.
Second, our study provides strong evidence that CDK activity influences the choice of DNA repair pathways in vivo. HR and NHEJ are 2 major pathways for repairing DSBs and are differentially utilized during the cell cycle (20, 43) . Suppressed HR upon induced quiescence likely leads to increased NHEJ dependence and involves several mechanisms, such as lack of HR repair templates due to G 1 arrest and loss of CHK1-mediated CtIP-dependent DNA end resection and CDK-mediated p-BRCA1 (Ser1497). The importance of NHEJ in repairing IR-induced DNA lesions in the intestine is further supported by the observations that deficiency in 53BP1 (44, 45) , poly(ADP-ribose) polymerase 1 (PARP1) (46), or DNA-PKcs (47) exacerbates crypt loss and tissue injury. These deficiencies are predicted to abrogate or attenuate the intestinal protection afforded by PD. Mutation in BRCA1/2 (48, 49) or compromised CDK1 in BRCA-proficient cancer cells (50) leads to defective HR and increased sensitivity to PARP inhibitors (PARPi). It is therefore tempting to speculate that CDKi induce a transient state of "BRCA-lessness" and NHEJ dependence or PARPi sensitivity and that p53 status plays a potential role in modulating patients' responses to CDKi/PARPi with DNA-damaging agents. However, the role and underlying mechanisms of increased NHEJ dependence in CDKi-mediated intestinal radioprotection need to be directly tested using mouse and cell models.
In addition, our study reveals a key role of LGR5 stem cells in IR-induced acute intestinal injury and regeneration, focusing on cell-intrinsic DDR using the well-characterized single, high-dose TBI model (1, 7, 22) . Stem cells are regulated by extracellular cues from the niche (51), while very little is known about how the niche regulates intestinal recovery from injury. The surprisingly potent synergic protection observed in the PD and PUMA-KO combination strongly suggests that the extent of ISC loss connects nichebased programs with tissue regeneration and stem cell activation, perhaps via damage-associated molecular patterns (DAMPs) (7) released from dying cells. However, our study cannot rule out the potential effects of CDKi in other cells. Study approval. The procedures for all animal experiments were reviewed and approved by the IACUC of the University of Pittsburgh.
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